Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15214888 | 0.98 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15214887 | 0.81 | CYP3A4 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL15214890 | 0.79 | NPSR1 (0.37) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL26835343 | 0.79 | CYP3A4 (0.33) | — | |
| SCHEMBL30602703 | 0.78 | FFAR3 (0.43) | — | |
| SCHEMBL6761647 | 0.77 | FFAR3 (0.31) | — | |
| SCHEMBL15116477 | 0.73 | USP2 (0.39) | ALDH1A1 | |
| SCHEMBL15116613 | 0.69 | GRIN2B (0.41) | SMN1; SMN2 | |
| SCHEMBL15116470 | 0.69 | GRIN2B (0.41) | SMN1; SMN2 | |
| SCHEMBL14828669 | 0.69 | GRIN2B (0.41) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170020869-A1 | Neuroprotective Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2017-01-26 | — | — | US | disclosed |
| US-20150258091-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-09-17 | — | — | US | disclosed |
| US-9119851-B2 | Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals | NEUREN PHARMACEUTICALS, LTD. (NZ) | 2015-09-01 | — | — | US | disclosed |
| US-20140309230-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-10-16 | — | — | US | disclosed |
| US-8791117-B2 | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2014-07-29 | — | — | US | disclosed |
| US-8519127-B2 | Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy | NEUREN PHARMACEUTICALS LIMITED (AU) | 2013-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309230-A1 | Cyclic Glycyl-2-Allyl Proline Improves Cognitive Performance in Impaired Animals | GRIA2, QPCT, GRM2 | ALDH1A1 1796/4885SMN1; SMN2 928/4885GRM1 36/4885 |
| US-20170020869-A1 | Neuroprotective Bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders | GRIN2C, GRIN2D, GRIN2A | ALDH1A1 1099/4885SMN1; SMN2 280/4885GRM1 26/4885 |
| US-20150258091-A1 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | GRIA2, GRIN2A, QPCT | ALDH1A1 1981/4885SMN1; SMN2 446/4885GRM1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.